shutterstock_1830418841_michael_vi
Michael Vi / Shutterstock.com
17 May 2022Big PharmaMuireann Bolger

Natera accuses CareDx of infringing DNA testing patents

Natera has accused rival medical company CareDx of infringing two patents covering its “cell-free” DNA (cfNDA) testing technology, Prospera.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Big Pharma
13 May 2021   Generics manufacturer Invitae has filed a lawsuit against rival company Natera claiming that its cancer detection test infringes one of Invitae’s DNA sequencing patents.
Big Pharma
14 May 2020   Natera has agreed to license Illumina IP covering non-invasive prenatal testing (NIPT), in a deal that sees the pair settle all outstanding patent litigation over the technology.
Americas
1 August 2023   The lawsuit alleged the unlawful use of cfDNA technology in RaDaR assay and related products | Adds to an existing legal action the company filed against Inivata.

More on this story

Big Pharma
13 May 2021   Generics manufacturer Invitae has filed a lawsuit against rival company Natera claiming that its cancer detection test infringes one of Invitae’s DNA sequencing patents.
Big Pharma
14 May 2020   Natera has agreed to license Illumina IP covering non-invasive prenatal testing (NIPT), in a deal that sees the pair settle all outstanding patent litigation over the technology.
Americas
1 August 2023   The lawsuit alleged the unlawful use of cfDNA technology in RaDaR assay and related products | Adds to an existing legal action the company filed against Inivata.

More on this story

Big Pharma
13 May 2021   Generics manufacturer Invitae has filed a lawsuit against rival company Natera claiming that its cancer detection test infringes one of Invitae’s DNA sequencing patents.
Big Pharma
14 May 2020   Natera has agreed to license Illumina IP covering non-invasive prenatal testing (NIPT), in a deal that sees the pair settle all outstanding patent litigation over the technology.
Americas
1 August 2023   The lawsuit alleged the unlawful use of cfDNA technology in RaDaR assay and related products | Adds to an existing legal action the company filed against Inivata.